Key clinical point: Cessation of calcitonin gene‐related peptide-receptor (CGRP-R) monoclonal antibody (mAb) prophylaxis worsens headache impact and health-related quality of life in patients with migraine.

Main finding: After 16 weeks from the last mAb injection, the mean Headache Impact Test-6 sum score increased by 3.69 (P < .001), mean EuroQol-5-Dimension-5-level declined by −0.07 (P = .013) and mean physical and mental component summary of Short Form-12 score deteriorated by −4.04 (P = .013) and −2.73 (P = .003), respectively.

Study details: This was a longitudinal, prospective cohort study involving 61 adult patients with episodic/chronic migraine receiving prophylaxis with a CGRP-R mAb (erenumab, n = 29; galcanezumab/fremanezumab, n = 32) for ≥8 months before a planned treatment cessation attempt.

Disclosures: The authors did not receive any financial support for the study. Some of the authors, including the lead author, reported serving on the advisory board of or receiving personal fees, speaker/consultant honoraria, and research grants from various organizations.

Source: Terhart M et al. J Headache Pain. 2021;22:158 (Dec 31). Doi: 10.1186/s10194-021-01368-7.

Key clinical point: Cessation of calcitonin gene‐related peptide-receptor (CGRP-R) monoclonal antibody (mAb) prophylaxis worsens headache impact and health-related quality of life in patients with migraine.

Main finding: After 16 weeks from the last mAb injection, the mean Headache Impact Test-6 sum score increased by 3.69 (P < .001), mean EuroQol-5-Dimension-5-level declined by −0.07 (P = .013) and mean physical and mental component summary of Short Form-12 score deteriorated by −4.04 (P = .013) and −2.73 (P = .003), respectively.

Study details: This was a longitudinal, prospective cohort study involving 61 adult patients with episodic/chronic migraine receiving prophylaxis with a CGRP-R mAb (erenumab, n = 29; galcanezumab/fremanezumab, n = 32) for ≥8 months before a planned treatment cessation attempt.

Disclosures: The authors did not receive any financial support for the study. Some of the authors, including the lead author, reported serving on the advisory board of or receiving personal fees, speaker/consultant honoraria, and research grants from various organizations.

Source: Terhart M et al. J Headache Pain. 2021;22:158 (Dec 31). Doi: 10.1186/s10194-021-01368-7.

Key clinical point: Cessation of calcitonin gene‐related peptide-receptor (CGRP-R) monoclonal antibody (mAb) prophylaxis worsens headache impact and health-related quality of life in patients with migraine.

Main finding: After 16 weeks from the last mAb injection, the mean Headache Impact Test-6 sum score increased by 3.69 (P < .001), mean EuroQol-5-Dimension-5-level declined by −0.07 (P = .013) and mean physical and mental component summary of Short Form-12 score deteriorated by −4.04 (P = .013) and −2.73 (P = .003), respectively.

Study details: This was a longitudinal, prospective cohort study involving 61 adult patients with episodic/chronic migraine receiving prophylaxis with a CGRP-R mAb (erenumab, n = 29; galcanezumab/fremanezumab, n = 32) for ≥8 months before a planned treatment cessation attempt.

Disclosures: The authors did not receive any financial support for the study. Some of the authors, including the lead author, reported serving on the advisory board of or receiving personal fees, speaker/consultant honoraria, and research grants from various organizations.

Source: Terhart M et al. J Headache Pain. 2021;22:158 (Dec 31). Doi: 10.1186/s10194-021-01368-7.

Key clinical point: Fremanezumab therapy led to significant reductions in patient-reported headache frequency and migraine pain intensity in patients with migraine.

Main finding: After fremanezumab initiation, the mean number of headache days/month reduced from 22.24 days preindex to 8.24 days postindex (P < .0001) and the mean visual analog scale pain score from 5.47 preindex to 4.51 postindex (P = .014).

Study details: This was a retrospective, observational cohort study including 172 adult patients with migraine who received fremanezumab (index event), had ≥6 months of enrollment/treatment history preindex and ≥1 month postindex along with no pregnancy event during the study.

Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc. The lead author received research support from and served as a consultant for various organizations including Teva. Some of the authors are current/former employees of Teva.

Source: McAllister P et al. J Headache Pain. 2021;22:156 (Dec 20). Doi: 10.1186/s10194-021-01358-9.

Key clinical point: Fremanezumab therapy led to significant reductions in patient-reported headache frequency and migraine pain intensity in patients with migraine.

Main finding: After fremanezumab initiation, the mean number of headache days/month reduced from 22.24 days preindex to 8.24 days postindex (P < .0001) and the mean visual analog scale pain score from 5.47 preindex to 4.51 postindex (P = .014).

Study details: This was a retrospective, observational cohort study including 172 adult patients with migraine who received fremanezumab (index event), had ≥6 months of enrollment/treatment history preindex and ≥1 month postindex along with no pregnancy event during the study.

Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc. The lead author received research support from and served as a consultant for various organizations including Teva. Some of the authors are current/former employees of Teva.

Source: McAllister P et al. J Headache Pain. 2021;22:156 (Dec 20). Doi: 10.1186/s10194-021-01358-9.

Key clinical point: Fremanezumab therapy led to significant reductions in patient-reported headache frequency and migraine pain intensity in patients with migraine.

Main finding: After fremanezumab initiation, the mean number of headache days/month reduced from 22.24 days preindex to 8.24 days postindex (P < .0001) and the mean visual analog scale pain score from 5.47 preindex to 4.51 postindex (P = .014).

Study details: This was a retrospective, observational cohort study including 172 adult patients with migraine who received fremanezumab (index event), had ≥6 months of enrollment/treatment history preindex and ≥1 month postindex along with no pregnancy event during the study.

Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc. The lead author received research support from and served as a consultant for various organizations including Teva. Some of the authors are current/former employees of Teva.

Source: McAllister P et al. J Headache Pain. 2021;22:156 (Dec 20). Doi: 10.1186/s10194-021-01358-9.

Key clinical point: The efficacy of fremanezumab for preventive treatment of difficult-to-treat migraine remains unaffected by age or sex.

Main finding: At week 12, quarterly and monthly fremanezumab reduced the monthly average of migraine days irrespective of age (18-45 years: quarterly, −4.1 days; monthly, −4.7 days; placebo, −0.9 days; >45 years: quarterly, −3.6 days; monthly, −3.7 days; placebo, −0.3 days; both P < .001) and sex (men: quarterly, −4.1 days; monthly, −4.6 days; placebo, −0.3 days; women: quarterly, −3.6 days; monthly, −3.9 days; placebo, −0.6 days; both P < .001).

Study details: This post hoc analysis of the phase 3b FOCUS trial included 837 adult patients with chronic/episodic migraine and an inadequate response to multiple alternative therapies, who were randomly assigned to quarterly fremanezumab, monthly fremanezumab, or placebo over 12 weeks.

Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc., PA. Some of the authors, including the lead author, received research funds or consultancy/speaker fees from various sources including Teva, which the rest were employees/stock owners of.

Source: MaassenVanDenBrink A et al. J Headache Pain. 2021;22:152 (Dec 18). Doi: 10.1186/s10194-021-01336-1.

Key clinical point: The efficacy of fremanezumab for preventive treatment of difficult-to-treat migraine remains unaffected by age or sex.

Main finding: At week 12, quarterly and monthly fremanezumab reduced the monthly average of migraine days irrespective of age (18-45 years: quarterly, −4.1 days; monthly, −4.7 days; placebo, −0.9 days; >45 years: quarterly, −3.6 days; monthly, −3.7 days; placebo, −0.3 days; both P < .001) and sex (men: quarterly, −4.1 days; monthly, −4.6 days; placebo, −0.3 days; women: quarterly, −3.6 days; monthly, −3.9 days; placebo, −0.6 days; both P < .001).

Study details: This post hoc analysis of the phase 3b FOCUS trial included 837 adult patients with chronic/episodic migraine and an inadequate response to multiple alternative therapies, who were randomly assigned to quarterly fremanezumab, monthly fremanezumab, or placebo over 12 weeks.

Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc., PA. Some of the authors, including the lead author, received research funds or consultancy/speaker fees from various sources including Teva, which the rest were employees/stock owners of.

Source: MaassenVanDenBrink A et al. J Headache Pain. 2021;22:152 (Dec 18). Doi: 10.1186/s10194-021-01336-1.

Key clinical point: The efficacy of fremanezumab for preventive treatment of difficult-to-treat migraine remains unaffected by age or sex.

Main finding: At week 12, quarterly and monthly fremanezumab reduced the monthly average of migraine days irrespective of age (18-45 years: quarterly, −4.1 days; monthly, −4.7 days; placebo, −0.9 days; >45 years: quarterly, −3.6 days; monthly, −3.7 days; placebo, −0.3 days; both P < .001) and sex (men: quarterly, −4.1 days; monthly, −4.6 days; placebo, −0.3 days; women: quarterly, −3.6 days; monthly, −3.9 days; placebo, −0.6 days; both P < .001).

Study details: This post hoc analysis of the phase 3b FOCUS trial included 837 adult patients with chronic/episodic migraine and an inadequate response to multiple alternative therapies, who were randomly assigned to quarterly fremanezumab, monthly fremanezumab, or placebo over 12 weeks.

Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc., PA. Some of the authors, including the lead author, received research funds or consultancy/speaker fees from various sources including Teva, which the rest were employees/stock owners of.

Source: MaassenVanDenBrink A et al. J Headache Pain. 2021;22:152 (Dec 18). Doi: 10.1186/s10194-021-01336-1.

Key clinical point: Routine clinical management of migraine using erenumab in occupationally active patients reduces the number of sick leave days and healthcare visits.

Main finding: Compared with the 12-month period before treatment initiation, a significant reduction in the number of headache-related sick leave days (4.9 vs. 1.3 sick leave days per patient-year; P = .035) and headache-related healthcare visits (4.9 vs. 2.7 visits per patient-year; P < .001) was observed over 12 months after treatment initiation.

Study details: This real-world retrospective registry analysis included 82 occupationally active patients with migraine who had 2 or more unique erenumab prescriptions and did not switch to an alternative calcitonin gene-related peptide inhibitor.

Disclosures: The study was supported by Novartis Finland Oy, Espoo, Finland. A few of the authors, including the lead author, declared serving as employees of Novartis Finland Oy while conducting the study. Amgen and Novartis have co-developed erenumab.

Source: Autio H et al. Neurol Ther. 2021 Dec 10. doi: 10.1007/s40120-021-00303-x.

Key clinical point: Routine clinical management of migraine using erenumab in occupationally active patients reduces the number of sick leave days and healthcare visits.

Main finding: Compared with the 12-month period before treatment initiation, a significant reduction in the number of headache-related sick leave days (4.9 vs. 1.3 sick leave days per patient-year; P = .035) and headache-related healthcare visits (4.9 vs. 2.7 visits per patient-year; P < .001) was observed over 12 months after treatment initiation.

Study details: This real-world retrospective registry analysis included 82 occupationally active patients with migraine who had 2 or more unique erenumab prescriptions and did not switch to an alternative calcitonin gene-related peptide inhibitor.

Disclosures: The study was supported by Novartis Finland Oy, Espoo, Finland. A few of the authors, including the lead author, declared serving as employees of Novartis Finland Oy while conducting the study. Amgen and Novartis have co-developed erenumab.

Source: Autio H et al. Neurol Ther. 2021 Dec 10. doi: 10.1007/s40120-021-00303-x.

Key clinical point: Routine clinical management of migraine using erenumab in occupationally active patients reduces the number of sick leave days and healthcare visits.

Main finding: Compared with the 12-month period before treatment initiation, a significant reduction in the number of headache-related sick leave days (4.9 vs. 1.3 sick leave days per patient-year; P = .035) and headache-related healthcare visits (4.9 vs. 2.7 visits per patient-year; P < .001) was observed over 12 months after treatment initiation.

Study details: This real-world retrospective registry analysis included 82 occupationally active patients with migraine who had 2 or more unique erenumab prescriptions and did not switch to an alternative calcitonin gene-related peptide inhibitor.

Disclosures: The study was supported by Novartis Finland Oy, Espoo, Finland. A few of the authors, including the lead author, declared serving as employees of Novartis Finland Oy while conducting the study. Amgen and Novartis have co-developed erenumab.

Source: Autio H et al. Neurol Ther. 2021 Dec 10. doi: 10.1007/s40120-021-00303-x.

Key clinical point: Noninvasive vagus nerve stimulation (nVNS) is an effective therapeutic option for preventing migraine.

Main finding: nVNS led to a greater mean reduction in monthly migraine days from baseline (3.12 days vs. 2.29 days; P = .2329) and a higher percentage of patients achieving ≥50% reduction in the number of migraine days (44.87% vs. 26.81%; P = .0481) compared to sham stimulation.

Study details: Findings are from the multicenter PREMIUM II trial wherein 231 adults with episodic or chronic migraine (with or without aura) were randomly assigned to receive nVNS (n = 114) or sham stimulation (n = 117) over 12 weeks. Of these, 113 (nVNS, n = 56; sham, n = 57) constituted the modified intention-to-treat population.

Disclosures: The study was sponsored by electroCore, Inc. Some of the authors, including the lead author, reported serving as a consultant/advisor/speaker for and receiving research grants from various organizations, including electroCore. E Liebler is an employee and stockholder of electroCore.

Source: Najib U et al. Cephalalgia. 2022  (Jan 9). Doi: 10.1177/03331024211068813.

Key clinical point: Noninvasive vagus nerve stimulation (nVNS) is an effective therapeutic option for preventing migraine.

Main finding: nVNS led to a greater mean reduction in monthly migraine days from baseline (3.12 days vs. 2.29 days; P = .2329) and a higher percentage of patients achieving ≥50% reduction in the number of migraine days (44.87% vs. 26.81%; P = .0481) compared to sham stimulation.

Study details: Findings are from the multicenter PREMIUM II trial wherein 231 adults with episodic or chronic migraine (with or without aura) were randomly assigned to receive nVNS (n = 114) or sham stimulation (n = 117) over 12 weeks. Of these, 113 (nVNS, n = 56; sham, n = 57) constituted the modified intention-to-treat population.

Disclosures: The study was sponsored by electroCore, Inc. Some of the authors, including the lead author, reported serving as a consultant/advisor/speaker for and receiving research grants from various organizations, including electroCore. E Liebler is an employee and stockholder of electroCore.

Source: Najib U et al. Cephalalgia. 2022  (Jan 9). Doi: 10.1177/03331024211068813.

Key clinical point: Noninvasive vagus nerve stimulation (nVNS) is an effective therapeutic option for preventing migraine.

Main finding: nVNS led to a greater mean reduction in monthly migraine days from baseline (3.12 days vs. 2.29 days; P = .2329) and a higher percentage of patients achieving ≥50% reduction in the number of migraine days (44.87% vs. 26.81%; P = .0481) compared to sham stimulation.

Study details: Findings are from the multicenter PREMIUM II trial wherein 231 adults with episodic or chronic migraine (with or without aura) were randomly assigned to receive nVNS (n = 114) or sham stimulation (n = 117) over 12 weeks. Of these, 113 (nVNS, n = 56; sham, n = 57) constituted the modified intention-to-treat population.

Disclosures: The study was sponsored by electroCore, Inc. Some of the authors, including the lead author, reported serving as a consultant/advisor/speaker for and receiving research grants from various organizations, including electroCore. E Liebler is an employee and stockholder of electroCore.

Source: Najib U et al. Cephalalgia. 2022  (Jan 9). Doi: 10.1177/03331024211068813.

Key clinical point: Erenumab led to decreased migraine frequency in patients with migraine with a history of aura.

Main finding: Compared with placebo, the change in monthly migraine days at week 12 was greater with 70 mg and 140 mg of erenumab in patients with episodic (least-squares mean differences [LSM] −1.1; 95% CI –1.7 to –0.6 and −0.9; 95% CI –1.6 to –0.2; respectively) and chronic (LSM −2.1; 95% CI –3.8 to –0.5 and −3.1; 95% CI –4.8 to –1.4, respectively) migraine with aura.

Study details: This was a post hoc subgroup analysis of 4 double-blind randomized clinical trials involving 2,443 adults with chronic or episodic migraine who received either erenumab (70 or 140 mg; n = 1,400) or placebo (n = 1,043).

Disclosures: Amgen Inc. sponsored the study. M Ashina reported being a principal investigator for ongoing trials for various sources including Amgen and, along with some co-authors, receiving speaking/teaching honoraria, advisory/consultation fees, or research grants from; or being a board member of, various companies. A few authors served as employees and stockholders of Amgen during the study period. Amgen and Novartis have co-developed erenumab.

Source: Ashina M et al. JAMA Neurol. 2021 (Dec 20). Doi: 10.1001/jamaneurol.2021.4678.

Key clinical point: Erenumab led to decreased migraine frequency in patients with migraine with a history of aura.

Main finding: Compared with placebo, the change in monthly migraine days at week 12 was greater with 70 mg and 140 mg of erenumab in patients with episodic (least-squares mean differences [LSM] −1.1; 95% CI –1.7 to –0.6 and −0.9; 95% CI –1.6 to –0.2; respectively) and chronic (LSM −2.1; 95% CI –3.8 to –0.5 and −3.1; 95% CI –4.8 to –1.4, respectively) migraine with aura.

Study details: This was a post hoc subgroup analysis of 4 double-blind randomized clinical trials involving 2,443 adults with chronic or episodic migraine who received either erenumab (70 or 140 mg; n = 1,400) or placebo (n = 1,043).

Disclosures: Amgen Inc. sponsored the study. M Ashina reported being a principal investigator for ongoing trials for various sources including Amgen and, along with some co-authors, receiving speaking/teaching honoraria, advisory/consultation fees, or research grants from; or being a board member of, various companies. A few authors served as employees and stockholders of Amgen during the study period. Amgen and Novartis have co-developed erenumab.

Source: Ashina M et al. JAMA Neurol. 2021 (Dec 20). Doi: 10.1001/jamaneurol.2021.4678.

Key clinical point: Erenumab led to decreased migraine frequency in patients with migraine with a history of aura.

Main finding: Compared with placebo, the change in monthly migraine days at week 12 was greater with 70 mg and 140 mg of erenumab in patients with episodic (least-squares mean differences [LSM] −1.1; 95% CI –1.7 to –0.6 and −0.9; 95% CI –1.6 to –0.2; respectively) and chronic (LSM −2.1; 95% CI –3.8 to –0.5 and −3.1; 95% CI –4.8 to –1.4, respectively) migraine with aura.

Study details: This was a post hoc subgroup analysis of 4 double-blind randomized clinical trials involving 2,443 adults with chronic or episodic migraine who received either erenumab (70 or 140 mg; n = 1,400) or placebo (n = 1,043).

Disclosures: Amgen Inc. sponsored the study. M Ashina reported being a principal investigator for ongoing trials for various sources including Amgen and, along with some co-authors, receiving speaking/teaching honoraria, advisory/consultation fees, or research grants from; or being a board member of, various companies. A few authors served as employees and stockholders of Amgen during the study period. Amgen and Novartis have co-developed erenumab.

Source: Ashina M et al. JAMA Neurol. 2021 (Dec 20). Doi: 10.1001/jamaneurol.2021.4678.

Key clinical point: In children with atopic dermatitis (AD), skin pain is a burdensome symptom with heterogeneous presentation and is associated with decreased quality of life (QoL).

Major finding: Skin pain intensity was associated with conditions such as bleeding (adjusted β 1.47; 95% CI 0.61-2.33), weeping/oozing (adjusted β 1.18; 95% CI 0.47-1.90), and cracking of skin (adjusted β 1.00; 95% CI 0.27-1.73). Parent-reported pain intensity was associated with impaired QoL in infants aged 1-4 years (adjusted β 1.16; 95% CI 0.18-2.14) and children aged 5-17 years (adjusted β 1.68; 95% CI 1.00-2.36).

Study details: Findings are from a cross-sectional national survey of 240 children with AD and their parents, of which 60 and 180 were aged 1-4 years and 5-17 years, respectively, and 200 had moderate-to-very severe disease.

Disclosures: This study was funded by the Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Cheng BT et al. J Allergy Clin Immunol Pract. 2021 (Dec 23). Doi: 10.1016/j.jaip.2021.12.012.

Key clinical point: In children with atopic dermatitis (AD), skin pain is a burdensome symptom with heterogeneous presentation and is associated with decreased quality of life (QoL).

Major finding: Skin pain intensity was associated with conditions such as bleeding (adjusted β 1.47; 95% CI 0.61-2.33), weeping/oozing (adjusted β 1.18; 95% CI 0.47-1.90), and cracking of skin (adjusted β 1.00; 95% CI 0.27-1.73). Parent-reported pain intensity was associated with impaired QoL in infants aged 1-4 years (adjusted β 1.16; 95% CI 0.18-2.14) and children aged 5-17 years (adjusted β 1.68; 95% CI 1.00-2.36).

Study details: Findings are from a cross-sectional national survey of 240 children with AD and their parents, of which 60 and 180 were aged 1-4 years and 5-17 years, respectively, and 200 had moderate-to-very severe disease.

Disclosures: This study was funded by the Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Cheng BT et al. J Allergy Clin Immunol Pract. 2021 (Dec 23). Doi: 10.1016/j.jaip.2021.12.012.

Key clinical point: In children with atopic dermatitis (AD), skin pain is a burdensome symptom with heterogeneous presentation and is associated with decreased quality of life (QoL).

Major finding: Skin pain intensity was associated with conditions such as bleeding (adjusted β 1.47; 95% CI 0.61-2.33), weeping/oozing (adjusted β 1.18; 95% CI 0.47-1.90), and cracking of skin (adjusted β 1.00; 95% CI 0.27-1.73). Parent-reported pain intensity was associated with impaired QoL in infants aged 1-4 years (adjusted β 1.16; 95% CI 0.18-2.14) and children aged 5-17 years (adjusted β 1.68; 95% CI 1.00-2.36).

Study details: Findings are from a cross-sectional national survey of 240 children with AD and their parents, of which 60 and 180 were aged 1-4 years and 5-17 years, respectively, and 200 had moderate-to-very severe disease.

Disclosures: This study was funded by the Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Cheng BT et al. J Allergy Clin Immunol Pract. 2021 (Dec 23). Doi: 10.1016/j.jaip.2021.12.012.

Key clinical point: Antibiotic use in infants younger than 12 months is associated with an increased risk of developing atopic dermatitis (AD) if shared familial and environmental factors are disregarded.

Major finding: A higher proportion of infants exposed (13.7%) vs. not exposed (13.4%) to antibiotics developed AD after 12 months of age. The risk of developing AD was higher in infants exposed to antibiotics in the first 12 months after birth (adjusted hazard ratio 1.12; 95% CI 1.04-1.21); however, this association disappeared when the data were matched with those obtained from their siblings.

Study details: Findings are from a retrospective, large-scale study including 85,954 infants, of which 10.1% were exposed to antibiotics at <12 months of age.

Disclosures: This study was funded by the Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research and the Project Promoting Clinical Trials for Development of New Drugs in Japan Agency for Medical Research and Development. Dr. Kawakami declared holding stock options and receiving research funds, consulting fees, and executive compensation from several sources.

Source: Tsuchida T et al. Acta Paediatr. 2021 (Dec 17). Doi: 10.1111/apa.16221.

Key clinical point: Antibiotic use in infants younger than 12 months is associated with an increased risk of developing atopic dermatitis (AD) if shared familial and environmental factors are disregarded.

Major finding: A higher proportion of infants exposed (13.7%) vs. not exposed (13.4%) to antibiotics developed AD after 12 months of age. The risk of developing AD was higher in infants exposed to antibiotics in the first 12 months after birth (adjusted hazard ratio 1.12; 95% CI 1.04-1.21); however, this association disappeared when the data were matched with those obtained from their siblings.

Study details: Findings are from a retrospective, large-scale study including 85,954 infants, of which 10.1% were exposed to antibiotics at <12 months of age.

Disclosures: This study was funded by the Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research and the Project Promoting Clinical Trials for Development of New Drugs in Japan Agency for Medical Research and Development. Dr. Kawakami declared holding stock options and receiving research funds, consulting fees, and executive compensation from several sources.

Source: Tsuchida T et al. Acta Paediatr. 2021 (Dec 17). Doi: 10.1111/apa.16221.

Key clinical point: Antibiotic use in infants younger than 12 months is associated with an increased risk of developing atopic dermatitis (AD) if shared familial and environmental factors are disregarded.

Major finding: A higher proportion of infants exposed (13.7%) vs. not exposed (13.4%) to antibiotics developed AD after 12 months of age. The risk of developing AD was higher in infants exposed to antibiotics in the first 12 months after birth (adjusted hazard ratio 1.12; 95% CI 1.04-1.21); however, this association disappeared when the data were matched with those obtained from their siblings.

Study details: Findings are from a retrospective, large-scale study including 85,954 infants, of which 10.1% were exposed to antibiotics at <12 months of age.

Disclosures: This study was funded by the Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research and the Project Promoting Clinical Trials for Development of New Drugs in Japan Agency for Medical Research and Development. Dr. Kawakami declared holding stock options and receiving research funds, consulting fees, and executive compensation from several sources.

Source: Tsuchida T et al. Acta Paediatr. 2021 (Dec 17). Doi: 10.1111/apa.16221.

Key clinical point: Children aged <5 years with atopic dermatitis (AD) show a disease severity-dependent increased risk for poor sleep health and attention dysregulation (AdR).

Major finding: AD-induced sleep disturbance on ≥5 nights/week was reported in 76% children with severe AD, 24% children with moderate AD, and none with mild AD (P = .01), and children with more severe AD had greater AdR (correlation coefficient 0.65; P < .01). Severity of AD was a significant predictor of poor sleep health (β 0.79; P < .01) and AdR (β 1.22; P < .01).

Study details: Findings are from a cross-sectional study including 60 children aged 1-4 years with mild-to-severe AD.

Disclosures: This study was supported by the Ann & Robert H. Lurie Children’s Hospital of Chicago and the Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Zhou NY et al. Pediatr Dermatol. 2021 (Dec 21). Doi: 10.1111/pde.14889.

Key clinical point: Children aged <5 years with atopic dermatitis (AD) show a disease severity-dependent increased risk for poor sleep health and attention dysregulation (AdR).

Major finding: AD-induced sleep disturbance on ≥5 nights/week was reported in 76% children with severe AD, 24% children with moderate AD, and none with mild AD (P = .01), and children with more severe AD had greater AdR (correlation coefficient 0.65; P < .01). Severity of AD was a significant predictor of poor sleep health (β 0.79; P < .01) and AdR (β 1.22; P < .01).

Study details: Findings are from a cross-sectional study including 60 children aged 1-4 years with mild-to-severe AD.

Disclosures: This study was supported by the Ann & Robert H. Lurie Children’s Hospital of Chicago and the Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Zhou NY et al. Pediatr Dermatol. 2021 (Dec 21). Doi: 10.1111/pde.14889.

Key clinical point: Children aged <5 years with atopic dermatitis (AD) show a disease severity-dependent increased risk for poor sleep health and attention dysregulation (AdR).

Major finding: AD-induced sleep disturbance on ≥5 nights/week was reported in 76% children with severe AD, 24% children with moderate AD, and none with mild AD (P = .01), and children with more severe AD had greater AdR (correlation coefficient 0.65; P < .01). Severity of AD was a significant predictor of poor sleep health (β 0.79; P < .01) and AdR (β 1.22; P < .01).

Study details: Findings are from a cross-sectional study including 60 children aged 1-4 years with mild-to-severe AD.

Disclosures: This study was supported by the Ann & Robert H. Lurie Children’s Hospital of Chicago and the Agency for Healthcare Research and Quality. The authors declared no conflicts of interest.

Source: Zhou NY et al. Pediatr Dermatol. 2021 (Dec 21). Doi: 10.1111/pde.14889.

Key clinical point: Onset and persistence of atopic dermatitis (AD) in children is associated with delinquent behaviors during childhood and adolescence.

Major finding: AD in children aged 5 years (adjusted odds ratio [aOR] 1.31; 95% CI 1.04-1.64) or 9 years (aOR 1.38; 95% CI 1.14-1.67) was associated with ≥75th percentile of mean delinquent behavior scores at age 9 or 15 years. At 9 years of age, a 1-year history of AD was associated with smoking at age 15 years (aOR 1.46; 95% CI 1.00-2.13), damaging property (aOR 1.38; 95% CI 1.08-1.77), cheating on a test (aOR 1.62; 95% CI 1.17-2.26), and school suspension (aOR 1.36; 95% CI 1.08-1.71).

Study details: Findings are from the prospective, longitudinal birth cohort Fragile Families and Child Wellbeing Study including 4,898 children aged 1, 3, 5, 9, or 15 years, of which 16.4%, 17.5%, and 16% of children aged 5, 9, and 15 years, respectively, had AD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Manjunath J et al. Arch Dermatol Res. 2022 (Jan 10). Doi: 10.1007/s00403-021-02314-y.

Key clinical point: Onset and persistence of atopic dermatitis (AD) in children is associated with delinquent behaviors during childhood and adolescence.

Major finding: AD in children aged 5 years (adjusted odds ratio [aOR] 1.31; 95% CI 1.04-1.64) or 9 years (aOR 1.38; 95% CI 1.14-1.67) was associated with ≥75th percentile of mean delinquent behavior scores at age 9 or 15 years. At 9 years of age, a 1-year history of AD was associated with smoking at age 15 years (aOR 1.46; 95% CI 1.00-2.13), damaging property (aOR 1.38; 95% CI 1.08-1.77), cheating on a test (aOR 1.62; 95% CI 1.17-2.26), and school suspension (aOR 1.36; 95% CI 1.08-1.71).

Study details: Findings are from the prospective, longitudinal birth cohort Fragile Families and Child Wellbeing Study including 4,898 children aged 1, 3, 5, 9, or 15 years, of which 16.4%, 17.5%, and 16% of children aged 5, 9, and 15 years, respectively, had AD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Manjunath J et al. Arch Dermatol Res. 2022 (Jan 10). Doi: 10.1007/s00403-021-02314-y.

Key clinical point: Onset and persistence of atopic dermatitis (AD) in children is associated with delinquent behaviors during childhood and adolescence.

Major finding: AD in children aged 5 years (adjusted odds ratio [aOR] 1.31; 95% CI 1.04-1.64) or 9 years (aOR 1.38; 95% CI 1.14-1.67) was associated with ≥75th percentile of mean delinquent behavior scores at age 9 or 15 years. At 9 years of age, a 1-year history of AD was associated with smoking at age 15 years (aOR 1.46; 95% CI 1.00-2.13), damaging property (aOR 1.38; 95% CI 1.08-1.77), cheating on a test (aOR 1.62; 95% CI 1.17-2.26), and school suspension (aOR 1.36; 95% CI 1.08-1.71).

Study details: Findings are from the prospective, longitudinal birth cohort Fragile Families and Child Wellbeing Study including 4,898 children aged 1, 3, 5, 9, or 15 years, of which 16.4%, 17.5%, and 16% of children aged 5, 9, and 15 years, respectively, had AD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Manjunath J et al. Arch Dermatol Res. 2022 (Jan 10). Doi: 10.1007/s00403-021-02314-y.